Sunny Abraham

This inventor holds 18 USPTO granted patents and 18 published patent applications and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Ambit Biosciences Corporation, Recurium IP Holdings, LLC, Vertex Pharmaceuticals, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sunny Abraham. Retrieved from https://idiyas.com/inventor/sunny-abraham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 18)

% Patents Active = 44.4

EPO Patents = 7 (Patent Applications = 23)

Average Co-Inventor Count = 8.2

ph-index = 4

Forward Citations = 50(Granted Patents)

Company Filing History:

8 out of 39

Ambit Biosciences Corporation

patents

8 out of 30

Recurium IP Holdings, LLC

patents

2 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

WEE1 Inhibitors

Cystic Fibrosis

EGFR Inhibitors

RAF Kinase Modulators

JAK Kinase Modulators

Chiral Synthesis

Spirocyclic Compounds

Tertiary Alcohols

Modulating Agents

Conductance Regulators

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753178 - Methods of making WEE1 inhibitor compounds (2026-10-06),

2. 12612416 - Modulators of cystic fibrosis transmembrane conductance regulator (2026-04-28),

3. 12421251 - Cystic fibrosis transmembrane conductance regulator modulating agents (2025-09-23),

4. 12410204 - Chiral synthesis of a tertiary alcohol (2025-09-09),

5. 12049460 - EGFR inhibitor compounds (2024-07-30),

6. 11261192 - Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones (2022-03-01),

7. 11098030 - EGFR inhibitor compounds (2021-08-24),

8. 10525036 - Spirocyclic compounds (2020-01-07),

9. 10513509 - EGFR inhibitor compounds (2019-12-24),

10. 10493060 - Spirocyclic compounds (2019-12-03),

11. 10053430 - RAF kinase modulator compounds and methods of use thereof (2018-08-21),

12. 9730937 - RAF kinase modulator compounds and methods of use thereof (2017-08-15),

13. 9320739 - RAF kinase modulator compounds and methods of use thereof (2016-04-26),

14. 9308207 - JAK kinase modulating compounds and methods of use thereof (2016-04-12),

15. 8969587 - RAF kinase modulator compounds and methods of use thereof (2015-03-03),

Title: The Innovative Journey of Sunny Abraham: A Pioneer in Cancer Treatment

Introduction: Sunny Abraham, an accomplished inventor based in San Diego, California, has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. With an impressive portfolio of 14 patents, he has dedicated his career to finding effective solutions for diseases characterized by excessive cellular proliferation.

Latest Patents: Sunny Abraham's most recent patents include a series of groundbreaking compounds aimed at targeting cancer. One of his notable innovations is the development of EGFR inhibitor compounds, which disclose nitrogen-containing bicyclic compounds that include pharmaceutically acceptable salts. These compounds are key in pharmaceutical compositions and methods designed to ameliorate and treat various cancers. Additionally, he has developed substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones, useful for treating diseases such as breast cancer. These inventions represent a significant advancement in the fight against some of the most challenging cancers.

Career Highlights: Throughout his career, Sunny Abraham has worked with prominent organizations, showcasing his commitment to advancing medical science. His tenure at Ambit Biosciences Corporation and Recurium IP Holdings, LLC, has facilitated the growth of his expertise and the impact of his inventions in the pharmaceutical industry.

Collaborations: Collaboration is key in the realm of innovation, and Sunny Abraham has had the privilege of working alongside talented individuals such as Qi Chao and Mark W. Holladay. These partnerships have enriched his research and contributed to the successful development of his patented compounds, highlighting the importance of teamwork in achieving groundbreaking results.

Conclusion: Sunny Abraham continues to be a driving force in the development of innovative solutions for cancer treatment. With his passion for research and dedication to invention, he plays a vital role in shaping the future of pharmaceuticals. As advancements in technology and science progress, inventors like Sunny Abraham pave the way for transformative therapies that hold the promise of improving countless lives.

Profile summary based on public USPTO records.